missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human APOBEC3D (aa 54-83) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (37%), Rat (37%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-63066 (PA5-63066. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
This gene is a member of the cytidine deaminase gene family. It is one of a group of related genes found in a cluster, thought to result from gene duplication, on chromosome 22. Members of the cluster encode proteins that are structurally and functionally related to the C to U RNA-editing cytidine deaminase APOBEC1 and inhibit retroviruses, such as HIV, by deaminating cytosine residues in nascent retroviral cDNA.
Specifications
Specifications
| Accession Number | Q96AK3 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 140564 |
| Name | Human APOBEC3D (aa 54-83) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | A3D; APOBEC3D; APOBEC3DE; APOBEC3E; apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3 D; apolipoprotein B mRNA editing enzyme catalytic subunit 3 D; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 D; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 E pseudogene; ARP6; DNA dC->dU-editing enzyme APOBEC-3 D; probable DNA dC->dU-editing enzyme APOBEC-3 D |
| Common Name | APOBEC3D |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction